Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

Table 2 Biomarkers for predicting outcomes with sorafenib

Ref.	Year	Obtained from	Biomarker
Llovet et al[16]	2012	Plasma	HGF, c-KIT
Miyahara et al[17]	2011	Serum	Angiogenesis-related cytokines1
Arao et al[18]	2013	Tissue	FGF3/FGF4
Huang et al[19]	2013	Tissue	αB-Crystallin
Hagiwara et al[20]	2012	Tissue	JNK
Abou-Alfa et al[21]	2006	Tissue	pERK
Shan et al[25]	2012	Cell line	Nanog
Blivet-Van Eggelpoël et al[26]	2012	Cell line	EGFR, HER-3
Chen et al[27]	2012	Cell line	SIRT1
Tai et al[28]	2011	Cell line	STAT3
Liu et al[4]	2006	Cell line	Mcl-1, eIF4E

¹These include angiopoietin-2, follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor. HGF: Hepatocyte growth factor; c-KIT: Also known as SCFR (mast/stem cell growth factor receptor); FGF: Fibroblast growth factors; JNK: c-Jun N-terminal kinase; pERK: Phosphorylated extracellular signal regulated kinase; EGFR: Epidermal growth factor receptor; HER-3: Also known as ErbB3; STAT3: Signal transducer and activator of transcription 3; Mcl-1: Myeloid cell leukemia-1; eIF4E: Eukaryotic translation initiation factor 4E.